

Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI

M. Vos^{1,2} , M. P. A. Starmans^{3,4} , M. J. M. Timbergen^{1,2}, S. R. van der Voort^{3,4}, G. A. Padmos³, W. Kessels^{3,4,6}, W. J. Niessen^{3,4,6}, G. J. L. H. van Leenders⁵, D. J. Grünhagen², S. Sleijfer¹, C. Verhoef², S. Klein^{3,4} and J. J. Visser³

Departments of ¹Medical and ²Surgical Oncology, Erasmus MC Cancer Institute, and Departments of ³Radiology and Nuclear Medicine, ⁴Medical Informatics and ⁵Pathology, Erasmus MC, Rotterdam, and ⁶Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands

Correspondence to: Ms M. Vos, Department of Surgical Oncology, Room Na-2117, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, the Netherlands (e-mail: m.vos.2@erasmusmc.nl)

Background: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from lipoma. Currently, this distinction is made by testing for *MDM2* amplification, which requires a biopsy. The aim of this study was to develop a noninvasive method to predict *MDM2* amplification status using radiomics features derived from MRI.

Methods: Patients with an *MDM2*-negative lipoma or *MDM2*-positive WDLPS and a pretreatment T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 2018 were included. When available, other MRI sequences were included in the radiomics analysis. Features describing intensity, shape and texture were extracted from the tumour region. Classification was performed using various machine learning approaches. Evaluation was performed through a 100 times random-split cross-validation. The performance of the models was compared with the performance of three expert radiologists.

Results: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and originated from 41 different MRI scanners, resulting in wide heterogeneity in imaging hardware and acquisition protocols. The radiomics model based on T1 imaging features alone resulted in a mean area under the curve (AUC) of 0.83, sensitivity of 0.68 and specificity of 0.84. Adding the T2-weighted imaging features in an explorative analysis improved the model to a mean AUC of 0.89, sensitivity of 0.74 and specificity of 0.88. The three radiologists scored an AUC of 0.74 and 0.72 and 0.61 respectively; a sensitivity of 0.74, 0.91 and 0.64; and a specificity of 0.55, 0.36 and 0.59.

Conclusion: Radiomics is a promising, non-invasive method for differentiating between WDLPS and lipoma, outperforming the scores of the radiologists. Further optimization and validation is needed before introduction into clinical practice.

Paper accepted 1 October 2019

Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11410

Introduction

Lipomatous tumours are the most commonly observed soft tissue tumours, mostly owing to the high incidence of benign lipomas. Also within the malignant spectrum of soft tissue tumours (soft tissue sarcomas), liposarcoma is among the most frequently observed subtype¹. Well differentiated liposarcoma (WDLPS) represents the largest subgroup of liposarcomas; these low-grade, locally aggressive tumours are characterized by amplification of the *MDM2* gene¹. In rare cases, WDLPS can progress into a more aggressive subtype: dedifferentiated liposarcoma (DDLPS), which has a poorer prognosis¹.

Several differences between lipoma and WDLPS on MRI have been described in the literature: size, location, tumour depth and intratumour heterogeneity. However, as there can be considerable overlap between these features, distinguishing between the two tumour types remains difficult, even for trained radiologists^{2–6}. As the differences between lipoma/WDLPS and DDLPS are more obvious, this distinction can accurately be made solely by eye^{5,7–10}.

An accurate diagnosis is needed to provide patients with the correct treatment and follow-up. Whereas lipomas do not necessarily need to be excised, patients with WDLPS are generally considered candidates for surgery¹¹.

Currently, the standard way to differentiate lipoma from WDLPS is through a biopsy, which is tested for *MDM2* amplification using fluorescence *in situ* hybridization (FISH). Amplification of the *MDM2* gene is present in WDLPS, but absent in lipoma^{1,12,13}. Taking a biopsy is an invasive and painful procedure for the patient, and is associated with risks, depending on tumour location, and potential sampling error.

The field of radiomics is based on the hypothesis that there is a relationship between medical imaging features and the underlying biological information, such as genetic aberrations¹⁴. Radiomics approaches have already been used in soft tissue sarcomas to predict other outcomes, such as differentiating between benign and malignant soft tissue tumours in general (not specifically lipomatous tumours)¹⁵, between intermediate- and high-grade soft tissue sarcomas¹⁶, and predicting the risk of lung metastases from soft tissue sarcoma of the extremities¹⁷. Based on these results, it was hypothesized that radiomics might also be able to differentiate WDLPS from lipoma.

The aim of this study was to develop a model that predicts *MDM2* amplification status using a radiomics approach, thereby differentiating WDLPS from lipoma. MRI scans obtained during routine diagnostic evaluation were used. Additionally, the performance of this model was compared with that of three trained radiologists reading the images. Finally, patients with DDLPS were included and classified by the radiologists to confirm that these tumours have distinct imaging features and can be identified without the help of additional models or tests.

Methods

Patients with a pathologically confirmed diagnosis of lipoma, WDLPS or DDLPS, a known *MDM2* amplification status tested by FISH, and with at least a T1-weighted MRI sequence available before treatment (if applicable) were included. All patients were either referred to/discussed at, or diagnosed/treated at the Erasmus MC Cancer Institute, Rotterdam, the Netherlands, between December 2009 and August 2018. As a result, some of the MRI scans were made in the referring hospitals. The study was reviewed and approved by the local medical ethics review committee (MEC-2016-339), and performed in accordance with national and international legislation. Need for informed consent was waived owing to the retrospective and anonymized nature of the study.

To explore the potential predictive value of different MRI sequences, several additional sequences were included, when available. Based on their use in clinical practice, the sequences were grouped into: plain T1

(T1); T1 with fat saturation (T1-FS) including T1 inversion recovery (IR) approaches (T1-IR; a combination of Spectral Presaturation with Inversion Recovery (SPIR), Short-TI Inversion Recovery (STIR), Spectral Attenuated Inversion Recovery (SPAIR) and Turbo Inversion Recovery Magnitude (TIRM)); T1 with gadolinium contrast (T1-GD); T1 with fat saturation and gadolinium contrast (T1-FS-GD) including T1-IR with GD; T2 imaging (T2) including T2-Fast Field Echo (T2FFE) and T2*; and T2-FS including T2-IR.

Segmentation

The lipoma and WDLPS lesions were segmented semi-automatically on the T1 images to indicate the regions of interest (ROIs)¹⁸. All images were segmented independently by either a medical masters student or a PhD candidate with an MD degree. Both were blinded to the type of lipomatous tumour. To validate segmentation accuracy, a sample set was verified by a musculoskeletal radiologist, specialized in soft tissue sarcomas. Median tumour size, defined as the maximum diameter in centimetres, and tumour volume, with corresponding i.q.r. values, were extracted from the segmentations. The DDLPS images were used only for visual classification by the radiologists, and therefore not segmented.


To transfer the segmentations to the other sequences, all sequences were spatially aligned to the T1 sequence using automated image registration (elastix software¹⁹), thereby compensating for patient movement between scans. Quality assurance was done by visual inspection.

Radiomics feature extraction

Quantitative imaging features related to intensity, shape and texture were extracted from the ROIs using PyRadiomics software^{20,21}. More details can be found in *Appendix S1* (supporting information). The shape features quantified were morphological properties such as volume and similarity to a circle. Intensity features were quantified using first-order statistics such as the mean and standard deviation. Texture features quantified more complex properties, such as the presence of heterogeneity and speckle patterns. When a scan type was missing for a patient, the feature values for the missing image type were imputed.

Additional features

Several additional features were selected based on the available literature and clinical relevance, including patient characteristics (age, sex and tumour location (extremity,



Inputs to the algorithm are T1- and T2-weighted magnetic resonance images of well differentiated liposarcoma (WDLPS) and lipoma (1). Processing steps include segmentation of the tumour on the T1 image (2), registration of the T1 to the T2 image to transform this segmentation to the T2 image (3), feature extraction from both the T1 and T2 images (4) and the creation of a decision model from the features (5), using an ensemble of the best 50 workflows from 100 000 candidate workflows; workflows are different combinations of the different processing and analysis steps (for example the classifier used).

trunk, head and neck or pelvis)) and manually scored features (tumour depth (superficial or deep), unilobular or multilobular tumour, atypical appearance on T1 image (yes or no)). These are referred to as patient and manually scored features respectively. Tumours were considered superficial when entirely located above the fascia, or as deep-seated when located beneath the fascia, or with invasion of the fascia.

Decision model creation

To create a decision model from the features, the Workflow for Optimal Radiomics Classification (WORC) toolbox²² was used. A schematic overview of the radiomics methodology is shown in Fig. 1. In WORC, decision model creation is divided into several steps. These steps include, for example, selection of features that offer the highest predictive value and machine learning to discover the patterns in these features that distinguish between WDLPS and lipoma. For each of these steps, numerous algorithms have been proposed in the literature. WORC performs an exhaustive search amongst these algorithms, in a fully automated way, and establishes the combination of algorithms that maximizes the prediction accuracy. As the single best solution may be a coincidental finding, the 50 best performing solutions were combined into a single

model, with the purpose of creating a more robust model and boosting performance. More details can be found in Appendix S2 (supporting information).

Experimental set-up

To assess the predictive value of the T1 imaging features, and the additional patient and manually scored features, five models were trained and tested based on: imaging features only (model 1); patient features only (model 2); manually scored features only (model 3); a combination of imaging features and manually scored features (model 4); and volume only (model 5). The fifth model was included because WDLPS is generally larger than lipoma³. Additionally, to investigate the potential of the features independent of volume, these five models were evaluated on a volume-matched cohort, that is a subset of the data in which the distribution of tumour volume was similar among WDLPS and lipoma. These models were trained on the full data set, but tested only on patients from the volume-matched cohort.

Next, the potential value of other MRI sequences was explored by training and testing multiple imaging-based radiomics models using combinations of the various MRI sequences. When a model showed more potential than

the T1 imaging-only model, it was evaluated on the volume-matched cohort as well.

Evaluation

Model evaluation was performed through cross-validation. The data were randomly split for 100 iterations, using 80 per cent for training and 20 per cent for testing. In each iteration, automatic workflow optimization was performed on the training set in an internal ten times random split cross-validation (Fig. S1, supporting information). Thus, the models were optimized solely on the training set; the test set was used only for evaluation of the final model. All splitting was done in a stratified manner to keep the balance between WDLPS and lipoma similar in all data sets.

Performance was evaluated using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve, accuracy, sensitivity, specificity, negative predictive value and positive predictive value, averaged over the 100 cross-validation iterations. Positive *MDM2* amplification status (WDLPS) was defined as the positive class. Ninety-five per cent confidence intervals for the mean performance measures were constructed using the corrected resampled *t* test based on all 100 cross-validation iterations, thereby taking into account that the samples in the cross-validation splits were not statistically independent²³.

Model insights

Insight into the model was gained by ranking the patients from typical to atypical for both lipoma and WDLPS, based on the consistency of the model predictions. This was determined by the number of times (percentage) that a patient was classified correctly when included in the test set. Typical examples were patients who were always classified correctly; and atypical vice versa. In addition, to identify the individual imaging features included in the radiomics model and to assess their respective contribution to the model, univariable statistical testing of the imaging features was undertaken using the Mann–Whitney *U* test. *P* values were corrected for multiple testing using the Bonferroni correction.

Classification by radiologists

Three radiologists with expertise in soft tissue tumours classified the lipomatous tumours; radiologists 1, 2 and 3 had 3, 10 and 5 years of experience respectively. First, the radiologists had to classify the tumours as either DDLPS or WDLPS/lipoma (non-DDLPS), to confirm that DDLPS can be recognized visually. Regardless of whether a tumour was classified as DDLPS or not, the tumours

subsequently had to be classified as *MDM2*-negative (lipoma) or *MDM2*-positive (WDLPS/DDLPS). The classification was done using a ten-point scale to indicate the certainty of the radiologists. The radiologists had access to all sequences that were available for each patient, as well as the age and sex.

Results

In total, 138 tumours were included: 58 patients had an *MDM2*-negative lipoma, 58 had an *MDM2*-positive WDLPS and 22 had an *MDM2*-positive DDLPS. Most patients were men (60.1 per cent) and had a deep-seated tumour located in a leg. Median WDLPS size was 20.4 cm and median volume was 36.3 cl, compared with 12.3 cm and 12.9 cl for lipoma (Table 1). Most of the patients underwent surgery: 32 with a lipoma, 50 with a WDLPS and 19 of those with a DDLPS. The eight patients with a WDLPS who did not have surgery were treated conservatively with an active surveillance approach, whereas the three with a DDLPS who did not have surgery had an inoperable tumour.

The 116 lipoma and WDLPS scans came from 41 different MRI scanners; there was wide heterogeneity in imaging

Table 1 Characteristics of the patients with lipomatous tumours

	No. of patients*(n = 138)
Age (years)†	64 (54–71)
Sex ratio (M : F)	83 : 55
Diagnosis	
Lipoma	58 (42.0)
WDLPS	58 (42.0)
DDLPS	22 (15.9)
Tumour location	
Upper extremity	14 (10.1)
Lower extremity	71 (51.4)
Trunk	37 (26.8)
Head and neck	6 (4.3)
Retroperitoneum and pelvis	6 (4.3)
Paratesticular	4 (2.9)
Tumour depth	
Superficial	20 (14.5)
Deep	118 (85.5)
Tumour size (cm)†	
Lipoma	12.3 (9.3–15.5)
WDLPS	20.4 (15.9–26.3)
Tumour volume (cl)†	
Lipoma	12.9 (4.6–25.0)
WDLPS	36.3 (22.9–85.5)

*With percentages in parentheses unless indicated otherwise; †values are median (i.q.r.). WDLPS, well differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma.

hardware and acquisition protocols used, reflected in differences in magnetic field strength (1.5 T, 98 scans; 1 T, 10 scans; 3 T, 8 scans), manufacturer (Siemens, Munich, Germany, 45 scans; Philips, Amsterdam, the Netherlands, 45 scans; GE, Chicago, Illinois, USA, 26 scans), scanner model (19 different ones), slice thickness, repetition time and echo time. Additional sequences besides T1 were available in subsets of patients: T1-FS in 55 patients (47.4 per cent), T1-GD in 42 patients (36.2 per cent), T1-FS-GD in 80 patients (69.0 per cent), T2 in 76 patients (65.5 per cent) and T2-FS in 92 patients (79.3 per cent) (Table S1, supporting information).

Evaluation of radiomics models based on T1 imaging and additional features

The performances of models 1–5 are shown in Fig. 2 and Table S2 (supporting information). Model 1, based on the T1 imaging features, resulted in an AUC of 0.83, sensitivity of 0.68 and specificity of 0.84. Model 2, based on patient features, had a lower AUC (0.75), higher sensitivity (0.77), but lower specificity (0.59). Similarly, model 3, based on manually scored features, also had a lower AUC (0.72), higher sensitivity (0.76) and lower specificity (0.57). Model 4, combining the imaging and manually scored features, performed worse than model 1, implying that imaging features are sufficient as input. Finally, model 5, based on volume alone, performed similarly to model 1 with an AUC of 0.83, sensitivity of 0.67 and specificity of 0.84. Although the performance metrics were similar for models 1 and 5, the ROC curves in Fig. 2 show some differences. The ROC curve for the volume model (Fig. 2e) has some sharp bends, while that for the T1 imaging model is smoother (Fig. 2a).

Evaluation of the radiomics models with additional MRI sequences

Most models with an additional MRI sequence had a similar performance to the T1 imaging model (Table S3, supporting information). However, the model combining the T1 and T2 imaging features showed a clear improvement in performance, with an AUC of 0.89, sensitivity of 0.74 and specificity of 0.88. The distribution of patient characteristics and the distribution of WDLPS and lipoma were similar across patients who had a T2 scan, indicating that the added value is within the T2 imaging features and not a result of incidental correlation with these characteristics, for example owing to selection bias.

Evaluation of models on volume-matched cohort

Model 5, based on volume alone, illustrated that volume is indeed a strong predictive factor. The 17 tumours with

a volume above 70 cl were all WDLPS, whereas the 21 tumours with a volume below 7 cl were all lipoma. In the volume-matched cohort, consisting of the other 78 tumours with a volume between 7 and 70 cl, the volume distributions for WDLPS and lipoma were more similar. As only the T2 scans provided additional value over the T1 imaging features, the T1 + T2 imaging model was evaluated for the volume-matched cohort as well.


The performance of both imaging-based models (T1 and T1 + T2) was worse on the volume-matched cohort (T1: AUC 0.69; T1 + T2: AUC 0.81) (Table 2) than on the entire cohort (AUC 0.83 and 0.89 respectively) (Table S3, supporting information). The models based on the patient and manually scored features performed similarly to the models tested on the full cohort. The model based on volume alone still performed above chance (mean AUC 0.64), but considerably worse than on the entire data set. In this volume-matched data set, both the T1 imaging model (AUC 0.69, sensitivity 0.60, specificity 0.74) and the T1 + T2 imaging model (AUC 0.81, sensitivity 0.66, specificity 0.84) performed considerably better than volume alone (Table 2). This showed that these models were not based solely on volume, and that other features provided additional predictive value over volume.

Model insights

Of the 116 lipomatous tumours, 69 (26 WDLPS, 43 lipoma) were always classified correctly by model 1 in all 100 cross-validation iterations. In contrast, 13 tumours (9 WDLPS, 4 lipoma) were always classified incorrectly. Fig. 3 shows four MRI slices of such typical and atypical examples of lipoma and WDLPS. The lesions that were always classified incorrectly were checked for possible sampling error of the biopsy. The *MDM2* amplification status of eight of the 13 tumours always classified incorrectly was already determined on the resection specimen (6 WDLPS, 2 lipoma). For the other five patients, in whom it was tested on the biopsy (3 WDLPS, 2 lipoma), pathological examination of the resection specimen confirmed the diagnosis, except for one patient with a lipoma who did not undergo surgery. In the other patient with a lipoma, the resection specimen again tested negative for *MDM2* amplification. The three WDLPS resection specimens were not retested.

Analysis of feature importance was done for the volume-matched cohort, as the results on the full data set were dominated by volume-related measures. In total, 16 individual features were found to be significant after Bonferroni correction on the volume-matched cohort (Fig. S2, supporting information). These included 11 shape features (including several volume-related statistics), four texture features and one intensity feature.

Fig. 2 Receiver operating characteristic (ROC) curves for the radiomics models based on the T1-weighted MRI sequence



a Using imaging features only, **b** using patient features only, **c** using manually scored features only, **d** using T1 imaging features combined with manually scored features, and **e** using volume only. The shaded area indicates the 95 per cent confidence intervals of the 100 times random-split cross-validation; the curve is fit through their means. The performance of the three radiologists is shown.


Radiomics models compared with radiologists

On the entire cohort, the AUCs of all three radiologists (0.74, 0.72 and 0.61 for radiologist 1, 2 and 3 respectively) (*Table S4*, supporting information) were below the lower

limit of the 95 per cent c.i. of the T1 imaging model (0.75 to 0.90) (*Fig. 2* and *Table S2*, supporting information), as well as of the 95 per cent c.i. of the T1 + T2 imaging model (0.83 to 0.95) (*Table S3*, supporting information). The

	T1 imaging features only	T1 + T2 imaging features	Patient features only	Manually scored features only	Volume only
AUC	0.69 (0.58, 0.80)	0.81 (0.72, 0.90)	0.74 (0.64, 0.84)	0.67 (0.56, 0.77)	0.64 (0.53, 0.74)
Accuracy	0.67 (0.57, 0.76)	0.75 (0.66, 0.83)	0.66 (0.56, 0.75)	0.60 (0.51, 0.69)	0.66 (0.57, 0.74)
Sensitivity	0.60 (0.45, 0.75)	0.66 (0.52, 0.79)	0.69 (0.55, 0.83)	0.70 (0.53, 0.87)	0.50 (0.36, 0.64)
Specificity	0.74 (0.60, 0.87)	0.84 (0.71, 0.96)	0.62 (0.48, 0.76)	0.51 (0.36, 0.65)	0.82 (0.71, 0.92)
NPV	0.66 (0.54, 0.77)	0.72 (0.60, 0.83)	0.68 (0.56, 0.79)	0.65 (0.49, 0.80)	0.62 (0.53, 0.71)
PPV	0.72 (0.58, 0.85)	0.81 (0.69, 0.93)	0.65 (0.54, 0.76)	0.59 (0.49, 0.69)	0.74 (0.61, 0.87)

Values are mean (95 per cent c.i.) over the cross-validation iterations. AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value.



a Typical lipoma, **b** atypical lipoma, **c** atypical well differentiated liposarcoma (WDLPS) and **d** typical WDLPS. The typical examples are from two patients always classified correctly by the T1 imaging model; the atypical examples are from two patients always classified incorrectly by the T1 imaging model.

radiologists achieved sensitivity values similar to (0.64 and 0.74) or higher (0.91) than those of the radiomics models (T1: 0.68; T1 + T2: 0.74), but their specificity was much lower (radiomics: 0.84 and 0.88 respectively; radiologists 1–3: 0.55, 0.36 and 0.59 respectively). The Cohen's κ value was 0.24, 0.04 and 0.40 for all pairs of radiologists, with a mean of 0.23, indicating poor interobserver agreement.

On the volume-matched cohort, the radiologists had a performance (AUC 0.68, 0.74 and 0.55) (Table S4,

supporting information) more similar to that of the T1 imaging model (AUC 0.69) (Table 2). On average, the T1 imaging model still performed better in terms of specificity (radiomics: 0.74; radiologists 1–3: 0.58, 0.37 and 0.50), whereas the radiologists again performed better on sensitivity (radiomics: 0.60; radiologists 1–3: 0.65, 0.88 and 0.60). However, the T1 + T2 imaging model performed much better (AUC 0.81, sensitivity 0.66, specificity 0.84) than both the T1 imaging model and the radiologists. On

this cohort, the Cohen's κ values were 0.18, -0.04 and 0.34 for all pairs of radiologists, with a mean of 0.16, again indicating poor interobserver agreement.

Distinction between dedifferentiated liposarcoma and well differentiated liposarcoma/lipoma

Besides classifying lipoma and WDLPS, the radiologists also classified the scans from 22 patients with DDLPS to evaluate whether DDLPS can indeed be identified by imaging only, without the help of additional models. Radiologists 1–3 had an AUC of 0.97, 0.91 and 0.90 respectively; a sensitivity of 0.95, 0.95 and 0.91; and a specificity of 0.95, 0.56 and 0.89 in distinguishing DDLPS from non-DDLPS (WDLPS/lipoma) (Table S4, supporting information).

Discussion

This study shows that there is a relationship between quantitative MRI features and *MDM2* amplification status, and that radiomics is a promising non-invasive method for differentiating lipoma from WDLPS. Although the radiologists were able to distinguish between DDLPS and non-DDLPS, they were outperformed by the T1 and T1 + T2 imaging models in differentiating WDLPS from lipoma. Moreover, the agreement between radiologists was very poor, whereas the radiomics-based predictions were objective and reproducible (given a tumour segmentation).

Remarkably, the model trained on volume alone had a similar performance to the T1 imaging model, which included many additional features. However, in the volume-matched data set, the T1 imaging model performed considerably better than the volume-only model, indicating that other features do provide additional predictive value. It is already known that WDLPS is on average larger than lipoma³, and the relationship with volume (or size) in our data set was also strong; the database did not contain lipoma larger than 70 cl or WDLPS smaller than 7 cl although these do exist^{24,25}. However, all WDLPS lesions start as small tumours and grow over time, so the measured tumour volume depends on the moment of presentation, and a small or intermediate tumour volume is therefore not a reliable biomarker. Future research should include expansion of the data set to make the volume distributions more representative (including lipoma larger than 70 cl and WDLPS smaller than 7 cl), thereby making the radiomics model less volume-dependent.

The models trained solely on either the patient or manually scored features performed slightly worse than the model trained on the T1 imaging features only. As the combined model did not outperform the T1 imaging

model, the manually scored features did not add much in the search for the best radiomics model. Additionally, the manually scored features may be observer-dependent, and thus prone to subjectivity. Although patient features (age, sex and tumour location) are objective, the distribution in the present data set may not be representative of clinical practice. For example, none of the patients with WDLPS were younger than 35 years, there were no lipomas among patients older than 82 years, no lipomas in the head and neck region, and no WDLPS in the pelvis or shoulder/trunk; all these might occur in daily clinical practice. Therefore, the imaging-only models have more potential as an objective tool in clinical practice.

The results of present study are similar to those of Thornhill and colleagues²⁶, who used a comparable approach and showed that lipomas can be distinguished from liposarcomas by texture and shape analysis. Strong points of the present study include the larger sample size (116 *versus* 44 in Thornhill *et al.*). Thornhill and co-workers also included other liposarcoma subtypes in their model, such as DDLPS and myxoid liposarcoma (8 of 20 included liposarcomas). These other liposarcoma subtypes have distinct radiological features^{5,10}, which in general can be easily discriminated from lipomas by experienced radiologists. By solely including the two tumour types that are the most difficult to distinguish (WDLPS and lipoma) in the radiomics model, the present data set is more challenging and more clinically relevant. In contrast to the cases described by Thornhill *et al.*, the diagnosis of all patients in the present data set was confirmed by verifying the *MDM2* amplification status using FISH, the current standard for diagnosing and differentiating between lipoma and WDLPS^{1,12,13}. The present radiomics model only requires routine MRI scans (T1, and optionally T2) without contrast injection; the other sequences did not add any predictive value to the model. As almost all standard MRI protocols include a T1 and T2 sequence, the present radiomics method is generalizable, feasible and applicable for use in daily practice. Finally, these radiomics models were developed and evaluated on a heterogeneous data set, thereby increasing the chance that the reported performance can be reproduced in a routine clinical setting when using other MRI scanners.

Advantages of using a radiomics approach over pathological assessment to differentiate between lipoma and WDLPS include sparing patients an invasive and painful biopsy, and saving the substantial costs of a radiologist performing the imaging-guided biopsy and of the pathologist assessing it, including the costs of molecular testing by FISH. Radiomics makes use of MRI images obtained during routine diagnostic evaluation and patients do not need

to undergo any additional procedure. When radiomics becomes a widely available tool, patients with WDLPS can be identified and referred to a soft tissue sarcoma expert centre at an earlier stage, with potential beneficial effects on further diagnostics, treatment and follow-up.

Several limitations of this study should be noted, besides the volume bias already mentioned. First, segmentation of ROIs of the tumours was done manually, which inherently leads to both interobserver and intraobserver variability, as has been quantified for other cancer types^{27–29}. Variability in segmenting the ROIs might lead to variability in the extracted imaging features and subsequently influence the classification of tumours. Additionally, manual segmentation is rather time-consuming. This could be addressed by use of automated segmentation tools that might be available in the future. Second, variation in imaging protocols might have influenced the imaging statistics. No restrictions were put on the T1 MRI sequences regarding field strength, slice thickness, or other MRI acquisition settings, as selecting a single protocol is an unrealistic reflection of daily clinical practice and would have made the results non-generalizable. Instead, this study shows that the present radiomics approach is robust to these variations by both training and testing the model on heterogeneous data. Third, the model is based on retrospectively collected data, which might have led to selection and information bias. This potential selection bias might have occurred particularly in the lipoma subgroup, as usually only large and atypical lipomas are referred to a sarcoma centre. However, this probably made the data set even more challenging and relevant, as these can be seen as the complex cases. Addition of the ‘small and typical’ lipomas would have made the classification easier, and radiomics is not needed to make the distinction for such lipomas.

The present radiomics model could serve as a non-invasive, quick and low-cost alternative to a biopsy. Although the model needs optimization to match the accuracy of a biopsy, there could be a certain patient group for whom the model may already be useful. For example, patients at high risk of complications of biopsy, or those in whom the radiomics model can predict the *MDM2* amplification status with a high degree of certainty, could already be treated according to the prediction of the radiomics model. Although further research is required to identify which patients could benefit most from the present model, initial misclassification of a WDLPS as a lipoma would not harm the patient, considering that active surveillance seems a safe option in patients without (invalidating) symptoms and/or tumour growth, at least in the short term³⁰. In addition, the performance of the radiomics model improved substantially when T2 images were added.

However, only 65.5 per cent of the patients had a T2 scan available, so for a follow-up study it is proposed to use MRI with at least both T1 and T2 sequences.

Acknowledgements

M.V. and M.P.A.S. contributed equally to this study. The authors thank E. H. G. Oei and D. F. Hanff for classifying the lipomatous tumours. This study was financed by the Stichting Coolensingel (reference no. 567), a Dutch non-profit foundation. M.P.A.S. acknowledges funding from the research programme STRaTeGy (project no. 14929-14930), which is partly financed by the Netherlands Organization for Scientific Research (NWO). W.J.N. is founder, scientific lead and stock holder of Quantib.

Disclosure: The authors declare no other conflicts of interest.

References

- 1 Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F; World Health Organization, International Agency for Research on Cancer. *WHO Classification of Tumours of Soft Tissue and Bone*. IARC Press: Lyon, 2013.
- 2 Brisson M, Kashima T, Delaney D, Tirabosco R, Clarke A, Cro S *et al.* MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: retrospective comparison with histology and *MDM2* gene amplification. *Skeletal Radiol* 2013; **42**: 635–647.
- 3 Kransdorf MJ, Bancroft LW, Peterson JJ, Murphey MD, Foster WC, Temple HT. Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma. *Radiology* 2002; **224**: 99–104.
- 4 Gupta P, Potti TA, Wuertzer SD, Lenchik L, Pacholke DA. Spectrum of fat-containing soft-tissue masses at MR imaging: the common, the uncommon, the characteristic, and the sometimes confusing. *Radiographics* 2016; **36**: 753–766.
- 5 Drevelegas A, Pilavaki M, Chourmouzi D. Lipomatous tumors of soft tissue: MR appearance with histological correlation. *Eur J Radiol* 2004; **50**: 257–267.
- 6 O'Donnell PW, Griffin AM, Eward WC, Sternheim A, White LM, Wunder JS *et al.* Can experienced observers differentiate between lipoma and well-differentiated liposarcoma using only MRI? *Sarcoma* 2013; **2013**: 982784.
- 7 Kransdorf MJ, Meis JM, Jelinek JS. Dedifferentiated liposarcoma of the extremities: imaging findings in four patients. *AJR Am J Roentgenol* 1993; **161**: 127–130.
- 8 Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N. Primary dedifferentiated liposarcoma of the retroperitoneum. Prognostic significance of computed tomography and magnetic resonance imaging features. *J Comput Assist Tomogr* 2003; **27**: 799–804.
- 9 Yun JS, Chung HW, Song JS, Lee SH, Lee MH, Shin MJ. Dedifferentiated liposarcoma of the musculoskeletal system:

- expanded MR imaging spectrum from predominant fatty mass to non-fatty mass. *Acta Radiol* 2019; doi: 10.1177/0284185119833060 [Epub ahead of print].
- 10 Murphey MD, Arcara LK, Fanburg-Smith J. From the archives of the AFIP: imaging of musculoskeletal liposarcoma with radiologic–pathologic correlation. *Radiographics* 2005; **25**: 1371–1395.
 - 11 ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; **25**(Suppl 3): iii102–iii112.
 - 12 Thway K, Wang J, Swansbury J, Min T, Fisher C. Fluorescence *in situ* hybridization for *MDM2* amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: experience at a tertiary center. *Sarcoma* 2015; **2015**: 812089.
 - 13 Kimura H, Dobashi Y, Nojima T, Nakamura H, Yamamoto N, Tsuchiya H *et al.* Utility of fluorescence *in situ* hybridization to detect *MDM2* amplification in liposarcomas and their morphological mimics. *Int J Clin Exp Pathol* 2013; **6**: 1306–1316.
 - 14 Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P *et al.* Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 2012; **48**: 441–446.
 - 15 Juntu J, Sijbers J, De Backer S, Rajan J, Van Dyck D. Machine learning study of several classifiers trained with texture analysis features to differentiate benign from malignant soft-tissue tumors in T1-MRI images. *J Magn Reson Imaging* 2010; **31**: 680–689.
 - 16 Corino VDA, Montin E, Messina A, Casali PG, Gronchi A, Marchianò A *et al.* Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. *J Magn Reson Imaging* 2018; **47**: 829–840.
 - 17 Vallières M, Freeman CR, Skamene SR, El Naqa I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Phys Med Biol* 2015; **60**: 5471–5496.
 - 18 Starmans MPA, Miclea RL, van der Voort SR, Niessen WJ, Thomeer MG, Klein S. Classification of malignant and benign liver tumors using a radiomics approach. In *SPIE Medical Imaging; 2018: Image Processing*; 10574D; 2018. <https://www.spiedigitallibrary.org/conference-proceedings-of-spie/10574/105741D/Classification-of-malignant-and-benign-liver-tumors-using-a-radiomics/10.1117/12.2293609.short?SSO=1> [accessed 9 September 2019].
 - 19 Klein S, Staring M, Murphy K, Viergever MA, Pluim JP. elastix: a toolbox for intensity-based medical image registration. *IEEE Trans Med Imaging* 2010; **29**: 196–205.
 - 20 GitHub. *Predict a Radiomics Extensive Differentiable Interchangeable Classification Toolkit (PREDICT)*. <https://github.com/Svdvoort/PREDICTFastr> [accessed 9 September 2019].
 - 21 van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V *et al.* Computational radiomics system to decode the radiographic phenotype. *Cancer Res* 2017; **77**: e104–e107.
 - 22 GitHub. *Workflow for Optimal Radiomics Classification (WORC)*. <https://github.com/MStarmans91/WORC> [accessed 9 September 2019].
 - 23 Nadeau C, Bengio Y. Inference for the generalization error. In *Advances in Neural Information Processing Systems?*, 2000; 307–313. <http://papers.nips.cc/paper/1661-inference-for-the-generalization-error.pdf> [accessed 9 September 2019].
 - 24 Sanchez MR, Golomb FM, Moy JA, Potozkin JR. Giant lipoma: case report and review of the literature. *J Am Acad Dermatol* 1993; **28**: 266–268.
 - 25 Smith CA, Martinez SR, Tseng WH, Tamurian RM, Bold RJ, Borys D *et al.* Predicting survival for well-differentiated liposarcoma: the importance of tumor location. *J Surg Res* 2012; **175**: 12–17.
 - 26 Thornhill RE, Golfam M, Sheikh A, Cron GO, White EA, Werier J *et al.* Differentiation of lipoma from liposarcoma on MRI using texture and shape analysis. *Acad Radiol* 2014; **21**: 1185–1194.
 - 27 Echegaray S, Gevaert O, Shah R, Kamaya A, Louie J, Kothary N *et al.* Core samples for radiomics features that are insensitive to tumor segmentation: method and pilot study using CT images of hepatocellular carcinoma. *J Med Imaging (Bellingham)* 2015; **2**: 041011.
 - 28 Lu L, Lv W, Jiang J, Ma J, Feng Q, Rahmim A *et al.* Robustness of radiomic features in [¹¹C]choline and [¹⁸F]FDG PET/CT imaging of nasopharyngeal carcinoma: impact of segmentation and discretization. *Mol Imaging Biol* 2016; **18**: 935–945.
 - 29 Parmar C, Rios Velazquez E, Leijenaar R, Jermoumi M, Carvalho S, Mak RH *et al.* Robust radiomics feature quantification using semiautomatic volumetric segmentation. *PLoS One* 2014; **9**: e102107.
 - 30 Vos M, Grünhagen DJ, Kosela-Paterczyk H, Rutkowski P, Sleijfer S, Verhoef C. Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. *Surg Oncol* 2019; **29**: 84–89.

Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.